Havas ECS:

The science behind the system

Havas ECS (Endocannabinoid Science) is an education and communications services company committed to health professional and consumer understanding of the endocannabinoid system, to better inform self-care, clinical decision making, and evidence-based reimbursement of medical cannabis and cannabinoid therapeutics.

Havas ECS offers educational programs that increase participant understanding, and communications solutions that engage health and medical stakeholders on behalf of manufacturers, employers, insurers, governments, and medical groups.

Therapeutic areas where cannabinoid
therapies are being researched

  • Alzheimer’s disease
  • Anorexia
  • Autism spectrum disorders
  • Autoimmune disease and inflammation
  • Bladder dysfunction
  • Cancer
  • Chronic pain
  • Epilepsy
  • Fragile X syndrome
  • Glaucoma
  • Insomnia
  • Migraine
  • Multiple sclerosis
  • Neonatal hypoxic-ischemic encephalopathy
  • Neuropathy (neuropathic pain)
  • Schizophrenia
  • Spinal cord injury

Havas ECS: Experience

Rob Dhoble headshot

Rob is an experienced communications executive, healthcare strategist, and leader of cross‑functional teams. Rob and his Havas team serve to advance the understanding of cannabinoid health and wellness, with science‑based education and communication programs that frame and elevate the cannabinoid conversation, and increase understanding of cannabinoid treatments and ECS‑related medical conditions.

Rob Dhoble, Managing Director
E: rob.dhoble@havas.com